Trinity Biotech plc (NASDAQ:TRIB) saw its stock increase by 4.4% following the announcement of promising clinical trial outcomes for its next-generation continuous glucose monitoring (CGM) system.
The biotech firm revealed that its newly engineered needle-free glucose sensor provided precise glucose measurements over a full 15-day wear period without the need for finger-stick calibration. This breakthrough marks a major step forward in developing Trinity’s CGM+ platform, which seeks to lower costs compared to existing market options by employing a modular design with fewer disposable parts.
“This milestone represents the most significant technical achievement since we began redevelopment of our acquired CGM technology,” stated John Gillard, CEO of Trinity Biotech. “The elimination of the requirement for finger-stick calibration was achieved through a combination of sensor design modifications, refined signal processing, and proprietary enhancements to sensor operation.”
The CGM+ device aims to consolidate multiple health metrics—including glucose levels, heart rate, body temperature, and physical activity—into one wearable biosensor. Trinity Biotech positions its technology as a cost-effective choice in the rapidly expanding CGM market, forecast to grow from about $13 billion in 2025 to nearly $28 billion by 2030.
These successful trial results overcome what the company described as “the most uncertain technical hurdle” in its development, paving the way for potential commercialization and regulatory approval of the CGM+ system.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.